Novo Nordisk shares experienced a sharp decline of up to 10% on Friday following the announcement that its late-stage trial for the experimental heart drug ziltivekimab failed to meet its primary endpoint of reducing major adverse cardiovascular events (MACE) compared to placebo [1]. The company stated that while ziltivekimab demonstrated some biological effect, it did not result in a statistically significant reduction in MACE, which includes cardiovascular death, non-fatal heart attack, or non-fatal stroke, in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammation [1].
Copenhagen-listed shares of Novo Nordisk were last seen down 7.4%, and its American depositary receipts dropped 8.6% in premarket trading following the news [1]. The trial enrolled more than 6,300 participants and tested whether ziltivekimab, which targets the inflammatory IL-6 pathway, could reduce the risk of a first major cardiovascular event when added to standard treatment [1]. Although overall adverse-event rates were similar between groups, serious infections were more common in the ziltivekimab arm, and there was no difference in overall mortality [1].
Novo Nordisk's chief scientific officer, Martin Holst Lange, commented, "While ziltivekimab did not achieve the MACE benefit we had hoped for, this does not change our strategic commitment to cardiovascular disease" [1]. The failed trial represents a significant setback for the Danish drugmaker, which has been working to restore investor confidence in its pipeline and execution, particularly in the competitive U.S. market [1].
Prior to the trial results, Novo Nordisk's Danish shares had already declined 7% year-to-date, and the announcement further exacerbated the downward trend, as highlighted in the company's ADR performance chart [1].
CONCLUSION
Novo Nordisk's failure to achieve the primary endpoint in its ziltivekimab heart drug trial triggered a significant sell-off in its shares, reflecting investor disappointment and concerns about the company's pipeline. The trial results mark a notable setback for Novo Nordisk's cardiovascular ambitions, though the company maintains its strategic commitment to the field.